InvestorPlace - Stock Market News, Stock Advice & Trading Tips. Ill be sticking to the stocks that are actually working. All rights reserved. It's easy to become such a huge fan of a stock that you lose objectivity about its prospects. Ocugen stated in a press release that it plans to "continue working with the FDA to evaluate the regulatory pathway for the pediatric use of Covaxin." The Motley Fool has no position in any of the stocks mentioned. Ocugen isnt a promotional, fly-by-night penny stock. The equity has experienced a continual decline for years. Its certainly possible. At the time, Ocugen was left for dead. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. The Motley Fool->. The short answer is: everything. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. An unprofitable biotech that focused on commercializing therapies to cure blindness prior to the present pandemic, Ocugen ( OCGN) stock took on a new life on December 22, when it announced. The FDA told the company in June 2021 that it should instead follow the standard path to full approval of the vaccine in adults. market." When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. While it feels cool to buy a thousand shares of OCGN stock vs. a few shares of Amazon (NASDAQ:AMZN), save yourself the heartache. 7 Travel Stocks to Buy Banking On Pent-Up Demand. Ocugen Chairman and CEO Shankar Musunuri Ocugen The company's stock opened at $8.24 per share Tuesday, up 96 cents. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. Emergency Use . Honestly, OCGN stock is unlikely to survive. So far, that merger hasnt worked out for Histogenics former shareholders. The company has a gene therapy platform as well as two preclinical compounds that aim to treat retinal diseases. Type a symbol or company name. Lorem ipsum dolor sit amet, consectetur adipiscing elit. The steep decline came after the company announced that the U.S. Food and Drug Administration (FDA) won't grant Emergency Use Authorization (EUA) for COVID-19 vaccine Covaxin in children ages two to 18. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. Instead, this appears destined to join the long list of failed biotech startups. The post There Are So Many Stocks to Buy Ocugen Isnt One of Them appeared first on InvestorPlace. Keith Speights has no position in any of the stocks mentioned. Nano-cap biotech play Ocugen has an intriguing story and a ton of risk. So, what goes wrong? Histogenics itself highlights the risks involved in small-cap biotech. If it goes down, your loss won't be as great as it would be if you held onto all of your shares. However, sometimes the optimism isn't justified. Type a symbol or company name. Making the world smarter, happier, and richer. COVID-19 vaccines from Pfizer and Moderna are already on the market in the U.S. with efficacy levels of 94% or greater. 1125 N. Charles St, Baltimore, MD 21201. The CanSinoBio partnership does help, but Ocugen still has a long way to go with OCU300. Indeed, the price broke below the 24 December 2018 low at 4.81 and is currently attempting a return move. Instead of buying a piece of the S&P 500 or Nasdaq or even better, a common sense mega-holding like Apple (NASDAQ:AAPL) or Amazon investors in OCGN stock took on a high-risk investment and for months saw negative returns. The stock dropped as low as 26 cents during the height of the pandemic fears in March 2020. If OCU300 is approved, theres a reasonably large market. Ocugen, previously a private company, instituted a reverse merger, which they completed on Sep. 30. Theres even room for more lines. The company stated that it will pursue a path to file for full FDA approval of Covaxin. Ocugen Inc. is a clinical stage biopharmaceutical company. After all, one cannot expect Ocugen stock to cure its ills when the company itself has fallen into critical condition. Ocugen announced in late Decemberit had signed a letter of intent to co-develop COVID-19 vaccine candidate Covaxin along with Indian pharmaceutical company Bharat Biotech. That's right -- they think these 10 stocks are even better buys. You never know when they will suddenly go on a squeeze. But it does mean something. The company has no revenue, runs an annual deficit, and does not generate positive free cash flow. But if they do, Ocugen stock at the least looks like an intriguing bet. Our 3 Top Picks. OCU300 already has received an orphan drug designation from the U.S. Food & Drug Administration for oGVHD; there is no currently approved treatment in the U.S. The generic form of brimonidine, the active ingredient, is not approved for the condition, according to Ocugens most recent presentation. While anything is possible, I would not anticipate a miracle here. Long-term debt of $1.6 million is not a back-breaker either. That product drives the current bull case for Ocugen stock. Under the terms of the agreement, Ocugen is entitled to 45% of the profits from the commercialization of Covaxin in the U.S. and Canada. In this case, shares rallied about four-fold in just a few days. Nasdaq According to the prospectus, the combined company posted an operating loss of roughly $30 million in 2018. The sale of NeoCart, which still is pending, can bring in another $8 million, based on the current agreement. In fact, the SPDR S&P 500 (NYSE:SPY) total return over the last 12 months is 34.2%. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. By the beginning of March, the stock was still trading at 45 cents as news of the coronavirus spreading in China prompted concerns about a U.S. pandemic. The point is, the risk/reward of owning something like Ocugen is simply not worth it vs. having even basic equity exposure. Do not expect this to become the biotech who made good like Biogen (NASDAQ:BIIB). Some investors had set their hopes on the FDA being more lenient with pediatric use of Covaxin. If youre not convinced by now, maybe you will consider OCGN stock a poor investment when looking at the fundamentals. Do Not Sell My Personal Information (CA Residents Only). For most of its history, what we now know as Ocugen stock was Histogenics, a cell therapy company focused on orthopedics. Ocugen shares jumped to $3.50 on massive volume in December when the Covaxin partnership was announced. This decision isn't surprising, considering that Ocugen previously abandoned the pursuit of an EUA path for the vaccine in adults. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! Cassava Sciences (NASDAQ:SAVA) has soared 454% in just the last three months. Ocugen has responded to Health Canada regarding deficiencies identified with its regulatory filing for Covaxin. *Average returns of all recommendations since inception. Maybe OCGN stock will be one of them again. Assuming it wins approval for the vaccine, the challenge for the company then will be to achieve commercial success. *Stock Advisor returns as of June 7, 2021. Now, with the stock trading near the 40-cent per share level, its prospects have taken a dramatic turn for the worse. From the outside looking inward, it looks like a marriage of two people who got together simply because nobody else would take them. These symbols will be available throughout the site during your session. But any success they find will be without me as a shareholder. And its at least possible that OCGN could wind up being a winner. Ocugen estimates the drug could have as many as 63,000 potential patients. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. Part of the proceeds will be used to support its partnership with Bharat. Biotech companies have emerged from similar levels to become huge winners, as evidenced simply by looking at some of the best biotech stocks for 2019. Shares of Ocugen ( OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based. However, I wont be around to find out. It is very important to do your own analysis before making any investment. Investors appear to expect that Bharat's big win for Covaxin in India could translate to success for Ocugen in the U.S. On Dec. 22, Ocugen and Bharat announced a binding letter of intent to jointly develop Covaxin for the U.S. market. Some of the names will rally big, putting together epic squeezes that can double or triple the stock prices in just a few days. Matt McCall and the InvestorPlace Research Staff, statistics support having long-term exposure, Click here to see what Matt has up his sleeve now, There Are So Many Stocks to Buy Ocugen Isnt One of Them. The agreement stipulates Ocugen will hold the vaccines U.S. rights, and the remaining details are expected to be finalized over the coming weeks. 2023 InvestorPlace Media, LLC. Investors need to understand the risk profile here. ET by MarketWatch Automation Ocugen Inc. stock falls Tuesday, underperforms market Feb. 21, 2023 at 5:14. Matthew McCall left Wall Street toactually helpinvestors by getting them into the worlds biggest, most revolutionary trends BEFORE anyone else. As of 1:37 p.m. EST, the biopharmaceutical company's stock price was down more than 15%.. Axsome Therapeutics (NASDAQ:AXSM) had an equity value below $75 million in March 2017; its now worth over $3 billion after rising over 1,000% last year. I am all for a good opportunity, but I dont know why some investors insist on penny stocks. If you missed that action, you missed all the gains. The FDA's decision not to issue EUA really wasn't all that surprising, though. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide. Still, Ocugens balance sheet isnt as dire as its share price might suggest. This can prove to be a costly lesson to learn. The newly renamed Ocugen stock kept declining through year-end, but has managed to stage a bit of a rally in 2020, gaining 15% year-to-date. Biotechnology stocks like Ocugen (NASDAQ:OCGN) are among the markets riskiest plays. It has real products. But there is no question some big-name stocks performed better than others along the way. The FDA typically takes 60 days to accept a regulatory filing then 10 months to make an approval decision. All rights reserved. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. The S&P 500 has rallied 52.9% from the March low to its highs on August 6. All rights reserved. Without NeoCart, that burn likely comes down. Copy and paste multiple symbols separated by spaces. (To watch Ramakanths track record, click here), In contrast, all 3 other analysts who have recently posted an Ocugen review rate the stock a Buy. As with many biotech stocks, the most likely outcome is for the company to fail, and for shareholders to wind up with zero. You could sell some or all of your Ocugen shares and buy long-term call options on the stock. The potential synergies of such a union do not seem clear. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization. Cost basis and return based on previous market day close. The Motley Fool has a disclosure policy. Malvern-based biopharmaceutical company Ocugen completed its previously announced $100 million private stock sale. As of this writing, Matt did not hold a position in any of theaforementioned securities. Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. Can you feel the ground moving beneath your feet? Custom BMW. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. 7 Penny Stocks Poised for Explosive Growth in 2023, Ocugen Stock Is Not for the Faint of Heart. Investing is always a game of balancing risk and reward. Remember, though, that Moderna achieved this while working closely with the U.S. government (including receiving funding from Uncle Sam) and during a period when vaccines weren't widely available. However, even from this limited vantage point, OCGN appears destined to fail. Realistically, Ocugen is probably looking at potential approval of Covaxin in mid-2023 at the earliest. Maybe. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. If they invent a miracle treatment for a condition, the money will find its way to the stock. 1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell, 3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street, 2 Reasons to Avoid a Roth 401(k) for Your Retirement Savings, Warren Buffett's Latest $2.9 Billion Buy Brings His Total Investment in This Stock to $66 Billion in 4 Years, Want $1 Million in Retirement? Disclaimer: The opinions expressed in this article are solely those of the featured analysts. How long might it take for Ocugen to win full FDA approval for Covaxin? ET on Friday. Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. Conditions only seem to get worse for Ocugen (NASDAQ:OCGN). Learn More. The second is that the balance sheet still needs some help. It means that raising capital will be more difficult going forward. The vaccine reportedly has a 78% efficacy rate against COVID-19, significantly lower than leading vaccines granted FDA emergency authorization. Probably the most important thing to do after Ocugen's crash, though, is to identify lessons learned and apply them to future investing decisions. Literally, zero. The Ocugen deal is a way to salvage some limited value. Start trading Options with Saxo today. Unfortunately for investors, the U.S. FDA did not grant Covaxin an Emergency Use Authorization and instead recommended in June that Ocugen opt for a Biologic License Application that will likely require additional Phase 3 testing. The Ocugen 52-week high stock price is 4.03, which is 328.7% above the current share price. The worst news was that another late-stage clinical study will likely be required to support the regulatory filing. How can we possibly evaluate a stock on a fundamental basis with that being reality? Emergency Use Authorization (EUA) for Covaxin, the COVID-19 vaccine developed by Ocugen's partner, Bharat Biotech. Those reverse splits generally are poorly received by the market, even if in theory they should have little to no practical impact on trading. In that list, you can even include penny-stock trader. 86% of retail CFD accounts lose money, Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023, Ocugen upgraded at Chardan citing attractive entry point ahead of catalysts, Analysts Are Bullish on These Healthcare Stocks: Theratechnologies (THTX), Ocugen (OCGN), Ocugen (OCGN) Gets a Buy from H.C. Wainwright, Mizuho Securities Sticks to Their Buy Rating for Ocugen (OCGN), Ocugen (OCGN) Q4 2022 Earnings Call Transcript, Why Catalyst Biosciences Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket, Registration on or use of this site constitutes acceptance of our. That said, for investors who understand the potential downside, there is an intriguing story here. *ALL INFO ABOUT THE BIKE AND GEAR USED DOWN BELOW**If not listed it's left stock*BIKE: 2018, BMW R NINET SCRAMBLER.EXHAUST: Akrapovic Headers, Uni. Ramakanth believes the broad immunity targeting different components of the virus could potentially provide better protection against emerging mutant viruses, such as the one currently circulating in the UK. With this in mind, in the Phase 1 study, COVAXIN has shown robust antibody responses against spike (S1) protein, receptor-binding domain (RBD) and the nucleocapsid (N) protein of SARS-CoV-2. Admittedly one could argue that it could have been bought for a quarter and sold for 75 cents, but hindsight is 20/20 in all of these names. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization (EUA) in India for COVID-19 vaccine Covaxin. Investors who have owned stocks in the last year have generally experienced some big gains. The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. Copyright In November, Bharat Biotech began Phase 3 testing of Covaxin in India. A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days later. 1125 N. Charles St, Baltimore, MD 21201. But the allure of the space is that when a company wins, its shareholders win big. Do Not Sell My Personal Information (CA Residents Only). It peaked at a split-adjusted level of around $778 per share soon after its initial public offering in 2014. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. The first is that Ocugen is facing potential delisting from the NASDAQ given that its share price still sits well below $1. Weve now already seen a 50% correction in the stock price, with shares changing hands around 46 cents per share. The Motley Fool recommends Moderna Inc. First, the balance sheet is in at least decent shape. OCGN does not even appear to have an apparent reason to exist. However, when that occurred, Ocugen stock lost most of its value. You canfollow Will on Twitterat @HealyWriting. Nor should one look forward to OCGN stock to becoming the next GW Pharmaceuticals (NASDAQ:GWPH) or Cara Therapeutics (NASDAQ:CARA). Hold) without suggesting a price target. UPDATE 1-Soccer-Traore on target as Wolves stun wasteful Spurs, Peruvian communities to resume blockade of crucial "mining corridor", One student loan forgiveness effort 'hasnt gotten the attention it deserves': expert, RPT-Death toll in strike on Ukraine's Zaporizhzhia rises to 11 - officials, Soccer-Traore on target as Wolves stun wasteful Spurs. The reverse merger with Histogenics was a disappointment, but the purchase price for the NeoCart intellectual property suggests that company had little chance of survival on its own. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Guys, theres no revenue here! Still, this stock is cheap for reasons that my colleague Josh Enomoto spelled out well. 2023 InvestorPlace Media, LLC. These options will be cheaper than owning the stock itself. See disclosure here. Generally, financial analysts struggle with this sector because these equities rise and fall not on revenue or earnings, but the success of clinical trials. To make the world smarter, happier, and richer. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. For now, the biggest near-term hope for Covaxin may be that Canada or another developed economy will buy the vaccine to share with developing nations. Ocugen does have at least 180 days to cure that problem, but the simplest answer is for the company to execute a reverse stock split. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Importantly, neither Bharat nor Indian regulators revealed the efficacy of the vaccine. Its top officers have experience at Pfizer (NYSE:PFE) and other well-respected pharmaceutical and biotechnology companies. Investors should definitely reevaluate Ocugen's prospects in light of the company's bad news announced last week. The broad point here is that, even with a ~$30 million market capitalization (based on updated share count information disclosed in an 8-K filing on Dec. 9), this is a company with a legitimate opportunity. The statistics support having long-term exposure to this asset class. Investors should worry about companies with no revenue even under the best of circumstances. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. Ocugen Inc., formerly known as Histogenics Cp, is based in Malvern, Pennsylvania. Why Everyone Is Investing in 5G All WRONG, Americas #1 Stock Picker Reveals His Next 1,000% Winner, Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company, Radical New Battery Could Dismantle Oil Markets. Related Link: If You Invested $1,000 In Moderna Stock One Year Ago, Here's How Much You'd Have Now. Names like Ocugen (NASDAQ:OCGN) arent trading for about 50 cents apiece by accident. However, due to the fact the details of the definitive agreement have yet to be finalized, in addition to the current lack of insight into the U.S. regulatory pathway or commercial strategy, Ramakanth stays on the sidelines for now. But the sale of NeoCart appears to not yet have closed after its deadline was extended to allow Medavate to secure financing. A $30 million market capitalization doesnt mean Ocugen has no chance. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! Almost all the headlines about Ocugen in the past year have been about the companys COVID-19 vaccine candidate. Thats not a new problem: a previous Phase 1/2 study, according to the prospectus, was discontinued early due to slow enrollment. The company noted that additional trials may be required as well. But just because a company does not have crippling debt doesnt mean its a buy. Conditions have only become worse since that time. The median estimate. Thats the thing with these low-priced penny stocks. In fact, $1,000 in Ocugen stock bought on Aug. 9, 2020, would be worth about $15,100 today. But realizing value in practice usually is a difficult endeavor. Moreover, Histogenics existed to treat orthopedic conditions, while Ocugen focused on rare eye diseases. Do not expect a recovery in Ocugen stock. Companies will inevitably be optimistic about their prospects for success (at least publicly). Create your Watchlist to save your favorite quotes on Nasdaq.com. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten.

Linden, Nj Police Reports, Articles O